Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields with Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
NCT05004025Phase 1Completed
- Sponsor
- HonorHealth Research Institute
- Start
- Feb 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in Uveal melanoma (UM), sponsored by HonorHealth Research Institute. Primary endpoints: Overall Response Rate at 1 year and Overall Safety at 1 year. Started Feb 2022; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05004025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004025.